Cargando…

Second Primary Malignancies in Patients with Colorectal Cancer: A Population‐Based Analysis

PURPOSE: This study aimed to profile the characteristics of patients with colorectal cancer (CRC) with a second primary malignancy (SPM) and to identify patients with CRC at high risk of developing SPMs. METHODS: We retrospectively reviewed data on patients with CRC aged 20–79 years from the Surveil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Huixun, Li, Qingguo, Yuan, Jing, Sun, Xiaodong, Wu, Zhenyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160402/ https://www.ncbi.nlm.nih.gov/pubmed/31943509 http://dx.doi.org/10.1634/theoncologist.2019-0266

Ejemplares similares

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

A Belgian Population-Based Study Reveals Subgroups of Right-sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer
por: Janssens, Katleen, et al.
Publicado: (2023)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Characteristics of colorectal carcinoma patients with PMS2 defects detected by immunohistochemistry
por: Zeng, Zhijun, et al.
Publicado: (2020)

The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
por: Li, Yaqi, et al.
Publicado: (2020)

Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases
por: Sutera, Philip, et al.
Publicado: (2018)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2023)

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)

Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review
por: Juat, Damie J, et al.
Publicado: (2022)

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study
por: Mentrasti, Giulia, et al.
Publicado: (2022)

Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early‐Onset Colorectal Cancer
por: Salem, Mohamed E., et al.
Publicado: (2021)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

Age–period–cohort effects in utilization of diagnostic procedures leading to incidental colorectal cancer detection
por: Salvatori, Andrea, et al.
Publicado: (2021)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)
por: García‐Albéniz, Xabier, et al.
Publicado: (2019)

Analysis of gastric and duodenal biopsy results in patients presenting with dyspepsia: a cross-sectional study in a middle eastern population
por: Ghosn, Youssef, et al.
Publicado: (2019)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
por: Best, Till Dominik, et al.
Publicado: (2021)

BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer
por: Tan, Elaine, et al.
Publicado: (2022)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Does CT colonography have a role for population-based colorectal cancer screening?
por: de Haan, Margriet C., et al.
Publicado: (2012)

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
por: Strickler, John H, et al.
Publicado: (2023)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Placenta-specific protein 1 enhances liver metastatic potential and is associated with the PI3K/AKT/NF-κB signaling pathway in colorectal cancer
por: Ma, Jiachi, et al.
Publicado: (2020)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation
por: Jensen, Garrett, et al.
Publicado: (2018)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait
por: Huey, Ryan W., et al.
Publicado: (2021)

Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)
por: Palmieri, Lola‐Jade, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hf2udgfm5lat42fae1pad3riq2